Stock Events

Stock Events

Assembly Biosciences 

$34.38
39
+$0.85+2.54% Friday 20:00
+$0.62+1.8%Friday 23:54After hours

Statistics

Day High
34.51
Day Low
34.34
52W High
39.71
52W Low
20.23
Volume
10,699
Avg. Volume
-
Mkt Cap
700M
P/E Ratio
342.5
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.8
-1.26
-0.73
-0.2
Expected EPS
-0.624275
Actual EPS
N/A

Financials

-8.47%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
72.3MRevenue
-6.12MNet Income

Analyst Ratings

46.00Average Price Target
The highest estimate is 50.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASMB. It's not an investment recommendation.
Microsoft
8
MSFT
Coca-Cola
7
KO
Apple
6
AAPL
3M
6
MMM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a leading biopharmaceutical company that competes with Assembly Biosciences in the development of treatments for viral diseases, including hepatitis B, which is a key focus area for Assembly Biosciences.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the pharmaceuticals sector focusing on therapies for chronic diseases, including hepatitis, directly competing with Assembly Biosciences' hepatitis B therapeutic development.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is involved in the discovery, development, and marketing of drugs for infectious diseases, including hepatitis B, making it a competitor to Assembly Biosciences.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb is a global biopharmaceutical company with a portfolio that includes viral infection treatments, competing with Assembly Biosciences in the hepatitis B market.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals incorporates innovative drug discovery and development, particularly in treating chronic diseases, which puts it in competition with Assembly Biosciences in the field of hepatitis B.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.24B
Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, including hepatitis B, making it a direct competitor to Assembly Biosciences.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for infectious diseases, including hepatitis B, positioning it as a competitor to Assembly Biosciences.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapeutics, with a focus on liver diseases including hepatitis B, competing with Assembly Biosciences' approach.

About

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Show more...
CEO
Jason A. Okazaki
Employees
73
Country
United States
ISIN
US0453962070
WKN
000A402CB

Listings

STU
DE
V7B.STU
MU
DE
V7B1.MU
STU
DE
V7B1.STU
MU
DE
V7B.MU

0 Comments

Share your thoughts

FAQ

What is Assembly Biosciences stock price today?▼
The current price of ASMB is $34.38 USD — it has increased by +2.54% in the past 24 hours. Watch Assembly Biosciences stock price performance more closely on the chart.
What is Assembly Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Assembly Biosciences stocks are traded under the ticker ASMB.
Is Assembly Biosciences stock price growing?▼
ASMB stock has risen by +4.34% compared to the previous week, the month change is a +36.32% rise, over the last year Assembly Biosciences has showed a +27.66% increase.
What is Assembly Biosciences market cap?▼
Today Assembly Biosciences has the market capitalization of 700M
When is the next Assembly Biosciences earnings date?▼
Assembly Biosciences is going to release the next earnings report on November 11, 2026.
What were Assembly Biosciences earnings last quarter?▼
ASMB earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.72 USD resulting in a +72.38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Assembly Biosciences revenue for the last year?▼
Assembly Biosciences revenue for the last year amounts to 72.3M USD.
What is Assembly Biosciences net income for the last year?▼
ASMB net income for the last year is -6.12M USD.
How many employees does Assembly Biosciences have?▼
As of August 23, 2026, the company has 73 employees.
In which sector is Assembly Biosciences located?▼
Assembly Biosciences operates in the Health & Wellness sector.
When did Assembly Biosciences complete a stock split?▼
The last stock split for Assembly Biosciences was on February 12, 2024 with a ratio of 1:12.
Where is Assembly Biosciences headquartered?▼
Assembly Biosciences is headquartered in SOUTH SAN FRANCISCO, United States.